Pharma IQ | 09/05/2010
Reto Ossola, Group Leader for Biomarket Research at Biognosys, joins Helen Winsor from Pharma IQ, to discuss phase I clinical development. He outlines where he sees the main challenges in biomarker development at the moment and discusses some key ways to address the cost-efficiency pressures. The interview also takes a look at partnerships - Ossola offers some best practice tips on assessing and working with a CRO, together with a summary of the main challenges in selecting partners and ens...
To continue reading this story Click Here
RECOMMENDED
MSD announces Phase III data on investigational treatment to lower LDL Cholesterol (LDL-C)
2025-11-17
AI for Pharma & Healthcare 2025
2025-06-18
Upcoming Events
Pharma Contract Manufacturing
23 - 25 March 2026
Mercure Hotel MOA Berlin, Germany
Register Now |
View Agenda |
Learn More